A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3365-3371

  Shibahara, Takuji ^a   Onishi, Takehisa ^a   Franco, Omar E ^b   Arima, Kiminobu ^a   Nishikawa, Kohei ^c   Yanagawa, Makoto ^c   Hioki, Takuichi ^d   Watanabe, Masatoshi ^e   Hirokawa, Yoshifumi ^a   Shiraishi, Taizo ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c SAISEIKAI MATSUSAKA GENERAL HOSPITAL   (Japan)

^d SUZUKA GENERAL HOSPITAL   (Japan)

^e YOKOHAMA NATIONAL UNIVERSITY   (Japan)

Author keywords

ARE1; Endocrine therapy; Prostate cancer; PSA polymorphism

Indexed keywords

ANDROGEN RECEPTOR; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN;

ALLELE; ARTICLE; DNA POLYMORPHISM; DNA RESPONSIVE ELEMENT; ENZYME ASSAY; GENE EXPRESSION; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; JAPAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RACE DIFFERENCE;

AGED; ANDROGENS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; JAPAN; MALE; NEOADJUVANT THERAPY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33750717167     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Armbruster DA: Prostate specific antigen: biochemistry, analytical methods and clinical application. Clin Chem 39: 181-195, 1993.
2. Smith DS, Catalona WJ and Herschman JD: Longitudinal screening of prostate cancer with prostate specific antigen. JAMA 276: 1309-1315, 1996.
3. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG and Henderson DR: Prostate-specific antigen is regulated by an upstream enhancer. J Biol Chem 271: 7043-7051, 1996.
4. Pang S, Dannulli J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB and Belldegrun AS: Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 57: 495-497, 1997.
5. Huang W, Shostaki Y, Tarr P, Sawyers C and Michael C: Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 274: 25756-25768, 1999.
6. Cleutjens K, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW and Trapman J: An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11: 148-161, 1997.
7. Cleutjens K, van Eekelen CC, van der Korput HA, Brinkmann AO and Trapman J: Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271: 6379-6388, 1996.
8. Chamberlain NL, Driver ED and Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22: 3181-3186, 1994.
9. Kazami-Esfarjani P, Triffino M and Pinsky L: Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenic relevance for the (CAG)n-expanded neuropathies. Hum Mol Genet 4: 523-527, 1995.
10. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR and Coetzee GA: Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9: 267-274, 2000.
11. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH and Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer, [published erratum appears in Proc Natl Acad Sci USA 94: 8272, 1997]. Proc Natl Acad Sci USA 94: 3320-3323, 1997.
12. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW and Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166-170, 1997.
13. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA and Ostrander EA: Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57: 1194-1198, 1997.
14. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Carvalho R and Lopes C: Linkage between polymorphisms in the prostate specific antigen ARE 1 gene region, prostate cancer risk, and circulating tumor cells. The Prostate 53: 88-94, 2002.
15. Wang L, Sato K, Tsuchiya N, Yu J, Ohyama C, Satoh S, Habuchi T, Ogawa O and Kato T: Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Letters 202: 53-59, 2003.
16. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA and Ingles SA: Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60: 839-841, 2000.
17. Rao A and Cramer SD: Identification of a polymorphism in the ARE1 region of the PSA promoter (abstract). Cancer Res 40: 60, 1999.
18. Sonnenberg A, Hogervorst F, Osterop A and Veltman FE: Identification and characterization of a novel antigen complex on mouse mammary tumor cells using a monoclonal antibody against platelet glycoprotein Ic. J Biol Chem 265: 14030-14038, 1998.
19. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA 277: 1445-1451, 1997.
20. Xue W, Coetzee GA, Ross RK, Irvine R, Kolonel L, Henderson BE and Ingles SA: Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 10: 575-579, 2001.
21. Gioeli D, Mandel JW, Petroni GR, Frierson HF and Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999.
22. Franco OE, Onishi T, Yamakawa K, Arima K, Yanagawa, M, Sugimura Y and Kawamura J: Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 56: 319-325, 2003.
23. Rao A, Chang B, Hawkins G, Hu JJ, Rosser CJ, Hall MC, Meyers DA, Xu J and Cramer SD: Analysis of G/A polymorphism in the androgen response element 1 of the PSA gene and its interactions with the androgen receptor polymprphisms. Urology 61: 864-869, 2003.
24. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke RT, Thomas LN, Bleecker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J and Xu J: Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 95: 1044-1053, 2003.
25. Gsur A, Preyer M, Haidinger G, Schatzl G, Madersbacher S, Marberger M, Vutuc C and Micksche M: Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23: 1647-1651, 2002.
26. Chiang CH, Chen KK, Chang LS and Hong CJ: The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J Urol 171: 1529-1532, 2004.
27. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J and Chatterjee S: Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170: 791-794, 2003.
28. Fukagai T, Mrita M, Yoshida H, Namiki T and Carlile R: The racial differences of prognosis after hormone treatment for prostate cancer. Jpn J Urol Surg 17: 955-957, 2004.